Le Lézard
Classified in: Health
Subjects: WOM, FDA

CrossBay Medical Announces FDA And CE Mark Marketing Authorizations For Its IVF Embryo Transfer Catheter Set


SAN FRANCISCO, May 17, 2017 /PRNewswire/ -- CrossBay Medical, Inc., today announced receipt of United States Food and Drug Administration (FDA) clearance of its product, the CrossBay IVF Embryo Transfer Catheter Set. The device has also received clearance to commercialize the product in Europe by obtaining its CE mark. The product is intended for ultrasound-guided transfer of embryos into the uterine cavity following in vitro fertilization. The embryo transfer procedure is the last step in the IVF process and critically important to the success of the procedure.

CrossBay Medical, Inc. (www.crossbaymedicalinc.com) was founded in 2009 with the goal of providing affordable healthcare products for women.

In 2012, there were approximately 1.76 million IVF cycles performed globally. While IVF has become the method of choice for infertile couples and infertility specialists, the average failure rate has remained unchanged over the past decade at approximately 70%.  Insertion and delivery problems associated with embryo transfer catheter techniques contribute significantly to this failure rate.  

"Embryo transfer is one of the most important parts of the IVF procedure, yet the technology has not advanced in 30 years. CrossBay's IVF Embryo Transfer Set is designed to alleviate many of the issues associated with embryo transfer to try and increase pregnancy rates," said Piush Vidyarthi, CEO of CrossBay Medical, Inc. "With FDA and CE clearance for our IVF Embryo Transfer Catheter Set we can now begin to streamline the way embryo transfer is performed with the ultimate goal of becoming the gold standard."

CrossBay Medical will pursue partnerships globally with entities that are equally driven to improve the IVF process for physicians and patients. In China, the company has entered into an exclusive distribution agreement with Peking Jabrehoo Med Tech Co., Ltd to commercialize the product. 

"We're thrilled to be working with a leading medical distributor in China that will begin commercialization efforts for the product once we receive marketing approval from the Chinese FDA.  CrossBay's goal has always been to offer effective products for the global market.  This distribution agreement will be the first step in our entry in the Chinese market," added Vidyarthi.

About CrossBay Medical, Inc.

CrossBay Medical, Inc. (www.crossbaymedicalinc.com) was founded in 2009 with the goal of providing affordable healthcare products for women. CrossBay Medical's products are designed in the United States, manufactured in China, and distributed by an existing network of affiliates. In addition to the IVF Embryo Transfer Catheter Set, the company's current portfolio of FDA and CE marked products also includes the SonoSure and SonoFlow products. With FDA and CE approval, CrossBay medical is now focused on bringing its products to market with the goal of improving women's healthcare globally.

Media Contact:
[email protected]

 

SOURCE CrossBay Medical, Inc.


These press releases may also interest you

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...

at 15:55
Valley Mountain Regional Center ("VMRC") experienced a data security incident that involved personal and / or protected health information belonging to certain current and former patients and has provided notice of this incident to impacted...



News published on and distributed by: